MRC Biotech is in negotiation with a partner to licence our Vitamin D3 portfolio for further clinical development. The existing granted patent portfolio provides a strong base for multiple opportunities in the anti-cancer field. Our publications provide evidence of the usefulness of this technology. 

Partners are also being sought to develop the non-cancer applications for MRC202, a VEGF inhibitor.  It is thought to have applications in AMD, heart disease and psoriasis.  For more information please contact David Andrews (david@mrcbiotech.com).